SGRY Stock Analysis: Surgery | NASDAQ
Medical Care Facilities | NASDAQ, USA | Market Cap: 1.885m USD | 12M Return: -37.2% | US86881A1007 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 29.3M
EPS Trend: -80.4%
Qual. Beats: 2
Rev. Trend: 97.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Surgery Partners, Inc. (NASDAQ: SGRY) owns and operates a U.S. network of ambulatory surgery centers and surgical hospitals that provide non-emergency procedures across specialties including orthopedics, ophthalmology, gastroenterology, and general surgery. Founded in 2004 and headquartered in Brentwood, Tennessee, the company also offers ancillary services such as physician practices, diagnostic testing, urgent care facilities, and anesthesia services, operating both single- and multi-specialty locations.
The company operates within the healthcare facilities sub-industry, where ambulatory surgery centers have grown as a lower-cost outpatient alternative to hospital-based procedures. Surgery Partners completed its IPO on October 1, 2015, and is classified as a small-cap stock with a market capitalization of approximately $1.89 billion USD.
- Outpatient surgical case volumes accelerate as procedures shift from hospitals
- Adjusted EBITDA margin expansion drives profitability
- Leverage reduction and refinancing lower interest expense
| Net Income: -88.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 0.13 > 1.0 |
| NWC/Revenue: 16.26% < 20% (prev 16.43%; Δ -0.17% < -1%) |
| CFO/TA 0.03 > 3% & CFO 258.0m > Net Income -88.6m |
| Net Debt (4.11b) to EBITDA (947.6m): 4.33 < 3 |
| Current Ratio: 1.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (128.8m) vs 12m ago 1.45% < -2% |
| Gross Margin: 21.37% > 18% (prev 23.74%; Δ -2.37% > 0.5%) |
| Asset Turnover: 42.07% > 50% (prev 40.69%; Δ 1.37% > 0%) |
| Interest Coverage Ratio: 1.15 > 6 (EBIT TTM 770.4m / Interest Expense TTM 668.0m) |
| A: 0.07 (Total Current Assets 1.13b - Total Current Liabilities 578.5m) / Total Assets 8.05b |
| B: -0.11 (Retained Earnings -866.1m / Total Assets 8.05b) |
| C: 0.10 (EBIT TTM 770.4m / Avg Total Assets 8.00b) |
| D: 0.34 (Book Value of Equity 1.67b / Total Liabilities 4.95b) |
| Altman-Z'' = 1.10 = BB |
| DSRI: 1.05 (Receivables 616.6m/563.1m, Revenue 3.37b/3.24b) |
| GMI: 1.11 (GM 23.74% / 21.37%) |
| AQI: 1.06 (AQ_t 0.72 / AQ_t-1 0.68) |
| SGI: 1.04 (Revenue 3.37b / 3.24b) |
| TATA: -0.04 (NI -88.6m - CFO 258.0m) / TA 8.05b) |
| Beneish M = -2.82 (Cap -4..+1) = A |
As of October 03, 2026, the stock is trading at USD 13.32 with a total of 1,228,073 shares traded. Over the past week, the price has changed by -7.50%, over one month by -4.72%, over three months by -22.69% and over the past year by -37.17%.
Current recommended Stop Loss: 12.30 (which is 7.7% or 1.3 ATR below the current price).
Surgery has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy SGRY.
- StrongBuy: 8
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 18.8 | 41.3% |
P/E Forward = 18.9036
P/S = 0.56
P/B = 1.1409
P/EG = 1.66
Revenue TTM = 3.37b USD
EBIT TTM = 770.4m USD
EBITDA TTM = 947.6m USD
Long Term Debt = 3.65b USD (from longTermDebt, last quarter)
Short Term Debt = 102.9m USD (from shortTermDebt, last quarter)
Debt = 4.32b USD (from shortLongTermDebtTotal, last quarter) + Leases 306.9m
Net Debt = 4.11b USD (calculated: Debt 4.32b - CCE 216.7m)
Enterprise Value = 5.99b USD (1.89b + Debt 4.32b - CCE 216.7m)
Interest Coverage Ratio = 1.15 (Ebit TTM 770.4m / Interest Expense TTM 668.0m)
EV/FCF = 31.95x (Enterprise Value 5.99b / FCF TTM 187.6m)
FCF Yield = 3.13% (FCF TTM 187.6m / Enterprise Value 5.99b)
FCF Margin = 5.57% (FCF TTM 187.6m / Revenue TTM 3.37b)
Net Margin = -2.63% (Net Income TTM -88.6m / Revenue TTM 3.37b)
Gross Margin = 21.37% ((Revenue TTM 3.37b - Cost of Revenue TTM 2.65b) / Revenue TTM)
Gross Margin QoQ = 22.41% (prev 15.01%)
Tobins Q-Ratio = 0.74 (Enterprise Value 5.99b / Total Assets 8.05b)
Interest Expense / Debt = 15.45% (Interest Expense 668.0m / Debt 4.32b)
Taxrate = 20.02% (20.5m / 102.4m)
NOPAT = 616.2m (EBIT 770.4m * (1 - 20.02%))
Current Ratio = 1.95 (Total Current Assets 1.13b / Total Current Liabilities 578.5m)
Debt / Equity = 2.59 (Debt 4.32b / totalStockholderEquity, last quarter 1.67b)
Debt / EBITDA = 4.33 (Net Debt 4.11b / EBITDA 947.6m)
Debt / FCF = 21.90 (Net Debt 4.11b / FCF TTM 187.6m)
Total Stockholder Equity = 1.70b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.11% (Net Income -88.6m / Total Assets 8.05b)
RoE = -5.21% (Net Income TTM -88.6m / Total Stockholder Equity 1.70b)
RoCE = 14.40% (EBIT 770.4m / Capital Employed (Equity 1.70b + L.T.Debt 3.65b))
RoIC = 8.32% (NOPAT 616.2m / Invested Capital 7.41b)
WACC = 11.12% (E(1.89b)/V(6.21b) * Re(8.28%) + D(4.32b)/V(6.21b) * Rd(15.45%) * (1-Tc(0.20)))
Discount Rate = 8.28% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.66 | Cagr: 1.00%
[DCF] Terminal Value 67.48% ; FCFF base≈182.7m ; Y1≈194.1m ; Y5≈230.2m
[DCF] Fair Price = N/A (negative equity: EV 2.40b - Net Debt 4.11b = -1.71b; debt exceeds intrinsic value)
EPS Correlation: -80.45 | EPS CAGR: -31.12% | SUE: 1.12 | # QB: 2
Revenue Correlation: 97.69 | Revenue CAGR: 9.11% | SUE: -0.46 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.12 | Chg30d=-6.61% | Revisions=-50% | Analysts=3
EPS current Year (2026-12-31): EPS=0.35 | Chg30d=-28.62% | Revisions=+55% | GrowthEPS=-26.2% | GrowthRev=-4.9%
EPS next Year (2027-12-31): EPS=0.28 | Chg30d=-55.36% | Revisions=-44% | GrowthEPS=-19.2% | GrowthRev=-10.5%
[Analyst] Revisions Ratio: -12% (up=9, down=12)